Aksiyel Spondiloartropati Tedavisine Güncel Yaklaşımlar

Yıl 2015, Cilt: 29 Sayı: 1, 57 - 64, 24.03.2016

Sema Yılmaz

Öz

Aksiyel spondiloartropati, omurgayı ve sakroiliak eklemleri tutan,
inflamatuar bel ağrısı ve ilerleyici omurga tutukluğuna neden olan kronik
inflamatuar romatolojik bir hastalıktır. Aksiyel spondiloartropati tedavisinin
amaçları; ağrı ve tutukluk gibi semptomları azaltmak, postürü korumak ve omurga
füzyonunu önlemektir. Ankilozan spondilitin aksiyel tutulumunda hastalık
modifiye edici anti-romatizmal ilaçların yararlı olduğuna dair kanıt bulunmamaktadır.
Steroid olmayan anti inflamatuar ilaçlar ve anti-tümör nekroz faktör alfa
ilaçlar, aksiyel spondiloartropati tedavisinde etkinliği olan ilaçlardır.

Anahtar Kelimeler

Aksiyel , spondiloartropati , tedavi

Kaynakça

• Referans1 Zochling J, Smith EU. Seronegative spondyloarthritis. Best Pract Res Clin Rheumatol 2010;24:747-756.
• Referans2 Onen F, Akar S, Birlik M, et al. Prevalence of ankylosing spondylitis and related spondyloarthritis in urban area of Izmir, Turkey. J Rheumatol 2008;35:305-309.
• Referans3 Robinson PC, Wordsworth BP, Reveille JD, Brown MA. Axial spondyloarthritis: a new disease entity, not necesssarily early ankylosing spondylitis. Ann Rhem Dis 2013;72:162-164.
• Referans4 Robinson PC, Brown MA. The genetics of ankylosing spondylitis and axial spondyloarthritis. Rheum Dis Clin North Am 2012;38:539-553.
• Referans5 Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815-822.
• Referans6 Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondyloarthritis: results fromtheGerman Spondyloarthritis Inception Cohort. Arthritis Rheum 2009;60:717-727.
• Referans7 Burgos-Vargas R, Braun J. Inflammatory back pain. Rheum Dis Clin North Am 2012;38:487-499.
• Referans8 Weisman MH. Inflammatory back pain: the United States perspective. Rheum Dis Clin North Am 2012;38:501-512.
• Referans9 Sieper J, van der Heijde D, Landewe R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009;68:784-788.
• Referans10 Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-783.
• Referans11 Braun J, van der Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
• Referans12 van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-908.
• Referans13 Passalent LA, Soever LJ, O’Shea FD, Inman RD. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol 2010;37:835-841.
• Referans14 Lubrano E, D’Angelo S, Parsons WJ, et al. Effectiveness of rehabilitation in active ankylosing spondylitis assessed by the ASAS response criteria. Rheumatology (Oxford) 2007;46:1672-1675.
• Referans15 Calin R, Elswood J. A prospective nationwide cross-sectional study of NSAI usage in 1331 patients with ankylosing spondylitis. J Rheumatol 1990;17:801-803.
• Referans16 Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondylarthritis: results from the German Spondylarthritis Inception Cohort 2012;71:1616-1622.
• Referans17 Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006;33:722-731.
• Referans18 Ward MM. Sulfasalazine for the treatment of ankylosing spondylitis: relic or niche medication? Arthritis Rheum 2011;63:1472-1474.
• Referans19 Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006;18:CD004524.
• Referans20 Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Muñoz-Valle JF, Gamez-Nava JI. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004;31:1568-1574.
• Referans21 Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 2014;73:243-246.
• Referans22 Braun J, Bollow M, Seyrekbasan F, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 1996;23:659-664.
• Referans23 Gunaydın I, Pereira PL, Daikeler T, et al. Magnetic resonance imaging guided corticosteroid injections of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol 2000;27:424-428.
• Referans24 McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158.
• Referans25 Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-863.
• Referans26 van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-929.
• Referans27 Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-345.
• Referans28 Cantini F, Niccoli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum 2006;55:812-816.
• Referans29 Haibel H, Sieper J. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker? Curr Opin Rheumatol 2010;22:388-392.
• Referans30 Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008;58:88-97.
• Referans31 Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor  inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-2654.
• Referans32 Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-715.
• Referans33 Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009;60:946-954.
• Referans34 Vander Cruyssen B, Munoz-Gomariz E, Font P, et al. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 2010;49:73-81.